二甲双胍治疗可恢复非酒精性脂肪性肝炎小鼠对免疫检查点抑制剂治疗的CD8+ T细胞应答
该研究在小鼠非酒精性脂肪性肝炎(NASH)模型中分析NASH对CD8+ T细胞依赖性抗PD-1应答的影响,发现NASH削弱抗PD-1治疗对肝癌的疗效,伴肝内CD8+ T细胞代谢与运动功能改变,二甲双胍治疗可恢复抗PD-1疗效。
要点
- NASH削弱小鼠抗PD-1治疗对肝癌的疗效。
- NASH导致肝内CD8+ T细胞代谢受损和肿瘤内运动性降低。
- 二甲双胍治疗可恢复NASH小鼠抗PD-1治疗的疗效。
核心结论
- NASH相关肝癌中CD8+ T细胞代谢发生关键改变,影响ICI治疗有效性,二甲双胍治疗可恢复NASH小鼠抗PD-1治疗对肝癌的疗效。
研究设计与样本
- 研究使用多种小鼠NASH模型,分析NASH对CD8+ T细胞依赖性抗PD-1应答的影响,比较正常饮食(ND)与NASH饮食小鼠CD8+ T细胞的转录组、功能和运动变化。
主要发现
- NASH在多种小鼠模型中削弱抗PD-1治疗对肝癌的疗效。
- NASH引起肝内CD8+ T细胞促炎表型改变。
- 转录组分析显示NASH依赖的肝内CD8+ T细胞代谢受损相关变化。
- 体内成像分析显示肿瘤内CD8+ T细胞运动性降低。
- 二甲双胍治疗恢复NASH小鼠抗PD-1治疗对肝肿瘤的疗效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Non-alcoholic steatohepatitis (NASH) represents the fastest growing underlying cause of hepatocellular carcinoma (HCC) and has been shown to impact immune effector cell function. The standard of care for the treatment of advanced HCC is immune checkpoint inhibitor (ICI) therapy, yet NASH may negatively affect the efficacy of ICI therapy in HCC. The immunologic mechanisms underlying the impact of NASH on ICI therapy remain unclear. METHODS: Herein, using multiple murine NASH models, we analysed the influence of NASH on the CD8+ T-cell-dependent anti-PD-1 responses against liver cancer. We characterised CD8+ T cells' transcriptomic, functional, and motility changes in mice receiving a normal diet (ND) or a NASH diet. RESULTS: NASH blunted the effect of anti-PD-1 therapy against liver cancers in multiple murine models. NASH caused a proinflammatory phenotypic change of hepatic CD8+ T cells. Transcriptomic analysis revealed changes related to NASH-dependent impairment of hepatic CD8+ T-cell metabolism. In vivo imaging analysis showed reduced motility of intratumoural CD8+ T cells. Metformin treatment rescued the efficacy of anti-PD-1 therapy against liver tumours in NASH. CONCLUSIONS: We discovered that CD8+ T-cell metabolism is critically altered in the context of NASH-related liver cancer, impacting the effectiveness of ICI therapy - a finding which has therapeutic implications in patients with NASH-related liver cancer. LAY SUMMARY: Non-alcoholic steatohepatitis represents the fastest growing cause of hepatocellular carcinoma. It is also associated with reduced efficacy of immunotherapy, which is the standard of care for advanced hepatocellular carcinoma. Herein, we show that non-alcoholic steatohepatitis is associated with impaired motility, metabolic function, and response to anti-PD-1 treatment in hepatic CD8+ T cells, which can be rescued by metformin treatment.
引用
- Wabitsch S, McCallen JD, Kamenyeva O, et al. Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD. J Hepatol. 2022. PMID: 35378172. doi:10.1016/j.jhep.2022.03.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。